Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Takeda Pharmaceutical Company Limited    4502   JP3463000004


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Takeda Pharmaceutical : Announcement of Making Nihon Pharmaceutical Co., Ltd. a Wholly-owned Subsidiary through Simple Share Exchange

11/25/2020 | 09:53am EST

Osaka - Takeda Pharmaceutical Company Limited (TSE: 4502 / NYSE: TAK) ('Takeda') today announced a share exchange where Takeda will be the wholly-owning parent company and Nihon Pharmaceutical Co., Ltd. ('Nihon Pharm'), Takeda's consolidated subsidiary, will be the wholly-owned subsidiary (the 'Share Exchange') effective April 1, 2021.

The two companies executed a share exchange agreement (the 'Share Exchange Agreement') today.

Since the acquisition of Shire in 2019, Takeda's Plasma-Derived Therapies (PDT) business has become one of the company's fastest areas of growth. As a result, the role played in the Takeda Group by Nihon Pharm, whose core business focus is plasma-derived therapies, has become more important than ever. The decision to make Nihon Pharm a wholly-owned subsidiary of Takeda is based on Takeda's values. It will strengthen collaboration across Takeda's PDT business in the best interest of patients, and further develop the business in and outside of Japan.

Takeda intends to conduct the Share Exchange in the form of a simple share exchange that does not require the approval of a shareholders' meeting pursuant to Article 796, paragraph (2) of the Companies Act. Since the Share Exchange is a simple share exchange through which a consolidated subsidiary will be made a wholly-owned subsidiary, this release is made in a simplified format.


Christopher O'Reilly

Tel: +81-(0)3-3278-2306

Email: takeda.ir.contact@takeda.com

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

Important Notice

For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could' 'anticipates', 'estimates', 'projects' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s) and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at : https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.

(C) 2020 Electronic News Publishing, source ENP Newswire

09:30aMODERNA : Says First Participant Dosed in COVID-19 Vaccine Phase 1/2 Study in Ja..
08:58aTAKEDA PHARMACEUTICAL : Clinical study begins in Japan for Moderna's COVID-19 va..
01/20TAKEDA PHARMACEUTICAL : Brazil antitrust regulator clears hurdle for Hypera-Take..
01/19TAKEDA PHARMACEUTICAL : Gets Canadian Regulatory Approval for Maintenance Treatm..
01/19TAKEDA PHARMACEUTICAL : to Hold Investor Call on January 29 During World Confere..
01/13TAKEDA PHARMACEUTICAL : KSQ Therapeutics Join Hands to Develop, Commercialize Ca..
01/11Drug makers help Nikkei scale fresh 3-decade high
01/11TAKEDA PHARMACEUTICAL : Projects 50% Surge in Revenue Growth Over Coming Decade;..
01/11TAKEDA PHARMACEUTICAL : Provides Pipeline Update and Shares Goal to Increase Rev..
01/11TAKEDA PHARMACEUTICAL : to Present at The 39th Annual J.P. Morgan Healthcare Con..
More news
Sales 2021 3 232 B 31 220 M 31 220 M
Net income 2021 201 B 1 938 M 1 938 M
Net Debt 2021 3 840 B 37 099 M 37 099 M
P/E ratio 2021 34,1x
Yield 2021 5,01%
Capitalization 5 614 B 54 184 M 54 231 M
EV / Sales 2021 2,93x
EV / Sales 2022 2,73x
Nbr of Employees 47 495
Free-Float 99,1%
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 13
Average target price 5 216,67 JPY
Last Close Price 3 591,00 JPY
Spread / Highest target 81,0%
Spread / Average Target 45,3%
Spread / Lowest Target 14,2%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Yasuhiko Yamanaka Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.18%427 472
ROCHE HOLDING AG3.56%308 129
NOVARTIS AG2.82%219 666
MERCK & CO., INC.0.81%208 627
PFIZER INC.-0.84%202 881